Research programme: KRS inhibitors - Yuhan CorporationAlternative Names: YH-Chem3; YH-chem4; YH_chem4
Latest Information Update: 16 Dec 2014
At a glance
- Originator Yuhan
- Class Small molecules
- Mechanism of Action Lysine tRNA ligase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer metastases
Most Recent Events
- 16 Dec 2014 Preclinical development is ongoing in South Korea
- 20 Aug 2012 Preclinical trials in Cancer metastases in South Korea (unspecified route)